Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
- Conditions
- IDH1-Mutated Malignancies
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 30
- Registration Number
- NCT07006688
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AMLChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 132
- Registration Number
- NCT06563804
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸The University of Kansas, Fairway, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 308
- Registration Number
- NCT06188702
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco (Ucsf) School of Medicine, San Francisco, California, United States
🇺🇸Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: S095024 RDEDrug: S095029 RDEDrug: S095018 Recommended Dose Expansion (RDE)
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 176
- Registration Number
- NCT06162572
- Locations
- 🇺🇸
Loma Linda University, Loma Linda, California, United States
🇺🇸University of Kansas Medical Center, Lawrence, Kansas, United States
🇺🇸Henry Ford Health, Detroit, Michigan, United States
Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen.
- Conditions
- Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 57
- Registration Number
- 2023-508507-20-00
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
- Prev
- 1
- 2
- Next